• Mashup Score: 2

    Positive high-level results from the BaxHTN Phase III trial showed baxdrostat at two doses (2mg and 1mg) demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) compared with placebo at 12 weeks. The trial also successfully met all secondary endpoints. Patients with uncontrolled or treatment resistant hypertension received baxdrostat or placebo on top of standard of care. Baxdrostat was generally well tolerated with a favourable safety

    Tweet Tweets with this article
    • #Baxdrostat at two doses (2mg and 1mg) demonstrated a statistically significant and clinically meaningful reduction in mean seated #SBP compared with placebo at 12 weeks. Met the primary and all secondary endpoints https://t.co/YaDfTNnvmn

  • Mashup Score: 112

    Abstract. Sepsis remains the most common cause of death in critically ill patients worldwide and the most frequent non-cardiac disease diagnosed in the Cor

    Tweet Tweets with this article
    • Sepsis-induced cardiomyopathy https://t.co/xcJ3NmBS23 #CardioEd @ESC_Journals @ehj_ed https://t.co/8C76mLxtSH